Literature DB >> 22038385

[Neuroimaging markers: their role for differential diagnosis and therapeutic decisions in personalized psychiatry].

O Gruber1.   

Abstract

In the context of personalized psychiatry there is growing interest in the development of neuroimaging markers for differential diagnosis and individualized therapy of mental disorders. This article reports on new neuroimaging markers for the diagnosis of Alzheimer's disease and particularly recent multi-functional magnetic resonance imaging (m-fMRI) studies in patients with schizophrenic and affective psychoses. Using experimental key paradigms for targeted assessment of pathophysiologically relevant neurofunctional systems, these studies reveal both differences and commonalities between the diagnostic categories. In addition, the article outlines research strategies for further development of the classification of major psychoses on the basis of a more precise characterization of the neurofunctional and pathophysiological phenotype. Multivariate approaches may help to identify more complex neuroimaging markers relevant for diagnosis and/or prognosis. Finally, some examples will be presented for the use of neuroimaging markers in the individualized choice of therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038385     DOI: 10.1007/s00115-011-3347-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  29 in total

Review 1.  Frontocingulate dysfunction in depression: toward biomarkers of treatment response.

Authors:  Diego A Pizzagalli
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

Review 2.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

3.  Oddball and incongruity effects during Stroop task performance: a comparative fMRI study on selective attention.

Authors:  Tobias Melcher; Oliver Gruber
Journal:  Brain Res       Date:  2006-10-04       Impact factor: 3.252

Review 4.  Cognitive neuropsychiatry: towards a scientific psychopathology.

Authors:  P W Halligan; A S David
Journal:  Nat Rev Neurosci       Date:  2001-03       Impact factor: 34.870

5.  Integrating neurobiological markers of depression.

Authors:  Tim Hahn; Andre F Marquand; Ann-Christine Ehlis; Thomas Dresler; Sarah Kittel-Schneider; Tomasz A Jarczok; Klaus-Peter Lesch; Peter M Jakob; Janaina Mourao-Miranda; Michael J Brammer; Andreas J Fallgatter
Journal:  Arch Gen Psychiatry       Date:  2010-12-06

Review 6.  [Neural correlates of working memory deficits in schizophrenic patients. Ways to establish neurocognitive endophenotypes of psychiatric disorders].

Authors:  O Gruber; E Gruber; P Falkai
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

Review 7.  [From identification of neurofunctional systems to individualization of treatment for schizophrenic disorders].

Authors:  O Gruber; P Falkai
Journal:  Nervenarzt       Date:  2009-01       Impact factor: 1.214

Review 8.  Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease--there is no schizoaffective disorder.

Authors:  Charles Ray Lake; Nathaniel Hurwitz
Journal:  Curr Opin Psychiatry       Date:  2007-07       Impact factor: 4.741

9.  Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study.

Authors:  Paul Lichtenstein; Benjamin H Yip; Camilla Björk; Yudi Pawitan; Tyrone D Cannon; Patrick F Sullivan; Christina M Hultman
Journal:  Lancet       Date:  2009-01-17       Impact factor: 79.321

10.  Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk.

Authors:  V Moskvina; N Craddock; P Holmans; I Nikolov; J S Pahwa; E Green; M J Owen; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2008-12-09       Impact factor: 15.992

View more
  5 in total

Review 1.  [Between psyche and brain : State of the art in psychiatry].

Authors:  T Fuchs
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

Review 2.  Multimodal functional and structural imaging investigations in psychosis research.

Authors:  C Christoph Schultz; Paolo Fusar-Poli; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Oliver Gruber; Heinrich Sauer; Ralf G M Schlösser
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-02       Impact factor: 5.270

3.  Common and disease-specific dysfunctions of brain systems underlying attentional and executive control in schizophrenia and bipolar disorder.

Authors:  Tobias Melcher; Sarah Wolter; Stefanie Falck; Eva Wild; Florian Wild; Eva Gruber; Peter Falkai; Oliver Gruber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-09-24       Impact factor: 5.270

4.  Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium.

Authors:  T G M van Erp; D P Hibar; J M Rasmussen; D C Glahn; G D Pearlson; O A Andreassen; I Agartz; L T Westlye; U K Haukvik; A M Dale; I Melle; C B Hartberg; O Gruber; B Kraemer; D Zilles; G Donohoe; S Kelly; C McDonald; D W Morris; D M Cannon; A Corvin; M W J Machielsen; L Koenders; L de Haan; D J Veltman; T D Satterthwaite; D H Wolf; R C Gur; R E Gur; S G Potkin; D H Mathalon; B A Mueller; A Preda; F Macciardi; S Ehrlich; E Walton; J Hass; V D Calhoun; H J Bockholt; S R Sponheim; J M Shoemaker; N E M van Haren; H E Hulshoff Pol; H E H Pol; R A Ophoff; R S Kahn; R Roiz-Santiañez; B Crespo-Facorro; L Wang; K I Alpert; E G Jönsson; R Dimitrova; C Bois; H C Whalley; A M McIntosh; S M Lawrie; R Hashimoto; P M Thompson; J A Turner
Journal:  Mol Psychiatry       Date:  2015-06-02       Impact factor: 15.992

Review 5.  Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.

Authors:  Oliver Gruber; Antonella Chadha Santuccione; Helmut Aach
Journal:  Front Psychiatry       Date:  2014-04-03       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.